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In 2013, 15 clusters of mumps were notified in France; 
72% (82/114) of the cases had been vaccinated twice 
with measles-mumps-rubella vaccine. To determine 
whether the risk of mumps increased with time since 
the last vaccination, we conducted a case–control 
study among clusters in universities and military bar-
racks. A confirmed case had an inflammation of a 
salivary gland plus laboratory confirmation in 2013. A 
probable case presented with inflammation of a sali-
vary gland in 2013 either lasting for > 2 days or with 
epidemiological link to a confirmed case. Controls 
had no mumps symptoms and attended the same uni-
versity course, student party or military barracks. We 
collected clinical and vaccination data via web ques-
tionnaire and medical records. We calculated adjusted 
odds ratios (aOR) using logistic regression. 59% 
(50/85) of cases and 62% (199/321) of controls had 
been vaccinated twice. The odds of mumps increased 
for twice-vaccinated individuals by 10% for every year 
that had passed since the second dose (aOR 1.10; 95% 
confidence interval (CI): 1.02–1.19; p = 0.02). Mumps 
immunity waned with increasing time since vacci-
nation. Our findings contributed to the French High 
Council of Public Health’s decision to recommend 
a third MMR dose during outbreaks for individuals 
whose second dose dates > 10 years.
Introduction
Mumps is a vaccine-preventable disease caused by an 
RNA virus of the paramyxoviridae family [1]. Typically, 
patients present with a febrile painful inflammation of 
a parotid gland [2,3]. The disease is generally benign 
with a spontaneous resolution but can lead to serious 
complications, notably in adult patients, such as orchi-
tis, meningitis, pancreatitis or encephalitis [2,3].
In France, mumps vaccination was first introduced into 
the childhood vaccination programme at the age of one 
year in 1986 with a trivalent measles-mumps-rubella 
(MMR) vaccine, containing the Urabe strain. Since 1993 
a trivalent vaccine containing the Jeryl Lynn strain has 
been used [4]. In 1996, a second dose was added for 
children aged 11–13 years [5]. The vaccination schedule 
was modified in the following years. In 1997, the age 
for the second dose was changed to 3–6 years [4] with 
a catch-up at 11–13 years for unvaccinated children. 
From 2005, the second dose was recommended in the 
second year of life, together with an extension of the 
catch-up for all individuals born from 1980 onwards 
[6]. However, for individuals born between 1980 and 
1992, one dose was considered sufficient. Since 2012, 
catch-up vaccination has been recommended with 
two doses for all individuals born from 1980 onwards 
[6]. A 2008–2009 school-based survey indicated that 
MMR vaccination coverage for children aged 15 years 
in France was 96% for the first and 84% for the second 
dose [7]. Data for vaccination coverage of young adults 
(over 15 years old) are not routinely collected in France.
Notification of mumps is not mandatory in France. 
However, as for all infectious diseases, unusual clus-
ters of cases must be reported to the regional health 
authorities, which then inform the French Institute of 
Public Health Surveillance (InVS). Since 1985, mumps 
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cases have been monitored by a sentinel network 
of general practitioners using a clinical case defini-
tion [2,8]. Between 1986 and 2012, mumps incidence 
recorded by the sentinel network decreased from 859 
cases per 100,000 to 6 cases per 100,000 [1,2,8].
In the spring of 2013, an upsurge of the disease was 
observed in mainland France. Clusters among adoles-
cents (11–17 years old) and young adults (18–29 years 
old), a majority of whom had been vaccinated with two 
doses of MMR, were reported to InVS. Of those, 15 clus-
ters of between 2 and 19 cases were among university 
students and soldiers in five regions (out of 22 regions in 
metropolitan France): Aquitaine, Champagne-Ardenne, 
Ile-de-France, Nord Pas-de-Calais and Rhône-Alpes. 
Similar outbreaks among highly vaccinated young 
adults have occurred in other countries during the past 
decade (e.g. Ireland from 2004 to 2008, Moldova and 
the United States (US) in 2008, the Netherlands from 
2009 to 2012, Israel in 2011) [2,9-12]. Those outbreaks 
were attributed to the accumulation of susceptible 
individuals in settings with opportunities for intense 
exposures (high level of proximity among people) and 
potential waning of vaccine-conferred immunity with 
time [13-16]. We aimed to determine whether the risk 
of mumps increases with an increasing interval of time 
since the last dose of MMR vaccination.
Methods
Study design
We conducted a multicentre case–control study with 
four regional offices of InVS and included all clusters 
notified in those regions between January and July 
2013.
Study population
The study population was young adults who belonged 
to a mumps cluster or attended either the same univer-
sity course or student party or were part of the same 
military unit.
Definitions
A cluster was defined as ≥ 2 cases, of whom minimum 
one was laboratory confirmed, occurring within 3 
Figure 
Selection procedure for mumps cases and controls, case-control study among young adults, France, 2013
Study population:
5,756 individuals who were part of a university course or student 
party or military unit where there were ≥2 mumps cases (5,652 
students and 104 soldiers)
Excluded:
• 8 self-declared cases not meeting case definition
• 23 controls with history of mumps
• 18 controlsa, not belonging to a cluster-unitb
• 5 cases and 71 controls without information on  vaccination status
Excluded:
• 15 cases and 28 controls not vaccinated
• 7 cases and 59 controls without vaccination dates 
• 3 cases and 7 controls with ≤3 weeks since last MMR dose 
Excluded:
• 14 cases and 55 controls with only one dose
Respondents (n=531):
427 students responded to web questionnaire and 104 soldiers 
were recruited via onsite investigation: 98 cases and 433 controls
Sub-analysis 1, vaccinated with 1 or 2 doses and date of last dose 
documented:
60 cases and 227 controls
Sub-analysis 2, vaccinated with 2 doses and date of second dose 
documented:
46 cases and 172 controls
Sample included in descriptive analysis: 
85 cases and 321 controls
 a These 18 individuals were non-cases who responded to the web questionnaire and were from the same university as the cases but did not 
attend the same university course or student party as the cases and thus were not classified as controls for the study.
b Cluster unit: ≥ 2 cases, of whom ≥ 1 was laboratory confirmed, occurring within three months in 2013 in the same environment (university 
course, student party or military barracks).
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months in 2013 in the same living environment (cluster 
unit).
A confirmed case was defined by the clinical symptoms 
(inflammation of a salivary gland) plus a laboratory 
confirmation (PCR from saliva and/or serology) in 2013.
A probable case was an individual with (i) uni- or bilat-
eral parotitis (self-reported or reported by doctor in 
medical records) in 2013 with duration of > 2 days or 
(ii) with a reported epidemiological link to a case if the 
duration was ≤ 2 days or (iii) if another salivary gland 
was involved.
A possible case was a person reporting a parotitis or 
inflammation of the sub-maxillary gland in 2013, but 
not fulfilling the criteria for a probable or a confirmed 
case.
Recruitment of controls
For the cases in students, we chose as controls all 
students without any reported symptoms of mumps 
who responded to the web questionnaire (see below) 
and who attended the same university courses or stu-
dent party as the cases. For the cases in soldiers, we 
chose as controls all soldiers from the same unit within 
the military barracks as the cases, and who had no 
recorded history of mumps. We aimed to have at least 
three controls per case.
Inclusion and exclusion criteria
We included only clusters for which we could obtain 
at least one control per case and all probable and 
confirmed cases that belonged to a cluster unit. We 
excluded possible cases in order to increase specificity 
and individuals without or with incomplete information 
on vaccination status. We excluded individuals who 
were vaccinated against mumps within 3 weeks before 
the onset of mumps or within 3 weeks before recruit-
ment as controls.
Data collection
Via email, we invited all students from each univer-
sity course with a mumps cluster to respond to a web-
based questionnaire, using Voozanoo 123 software 
(Epiconcept SA, France). We re-contacted individu-
als by telephone and email to complete missing data 
whenever possible. In some regions we visited univer-
sities in order to encourage participation.
Data from soldiers were collected via individual medi-
cal records and vaccination booklets during a visit to 
the barracks.
The questionnaire, which was completed by the stu-
dents, or by the investigators on behalf of the soldiers, 
covered demographic information, details about the 
cluster unit, mumps symptoms (self-reported for the 
university students and recorded by a medical doctor 
for the military personnel), laboratory test results, vac-
cination history and the source of vaccination informa-
tion (vaccination or health booklet, distributed at birth 
in France including all childhood vaccination records; 
medical files for soldiers).
Data analysis
We described probable and confirmed cases and 
controls (demographic data, cluster unit, vaccination 
status, and additionally for cases, symptoms, bio-
logical tests and case classification). Characteristics 
of cases and controls (age at the time of the study 
and at first MMR dose, sex, vaccination status, time 
interval between MMR doses) were compared using 
logistic regression. Vaccine effectiveness (VE) was 
calculated for one and two doses compared with 
unvaccinated individuals, according to the formula: 
VE = (1 – OR) * 100, with the OR calculated by multivari-
ate regression adjusted for sex.
For further analysis, we included only individuals for 
whom vaccination dates were recorded in a document. 
We calculated the mean number of years since the last 
dose for cases and controls. We used a multivariate 
logistic regression model for testing the association 
between the onset of mumps and the time since the 
last dose expressed as adjusted odds ratio (aOR). Time 
was modelled with a fractional polynomial. For cases 
and controls who had received at least one dose of vac-
cine, we adjusted for sex, age, cluster unit and number 
of MMR doses received. Independently, we looked only 
at cases and controls who had received two doses and 
adjusted for sex, age and cluster unit.
We described means and interquartile ranges (IQR) 
of the time interval between two doses for cases and 
controls and compared the intervals between the two 
groups using logistic regression.
Table 1
Characteristics and symptoms of mumps cases, case-
control study among young adults, France 2013 (n = 85)
Characteristics of cases n %












≤ 2 days 
> 2 days 










Complications Orchitis b 5 8.8





a Cluster unit: ≥ 2 cases, of which at least 1 was laboratory 
confirmed, occurring within 3 months in 2013 in the same 
environment (university course, student party or military 
barracks).
b Percentage of male cases only (n = 57).
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Based on the recommendation of the French High 
Council of Public Health (HCSP) to administer a third 
dose in outbreak settings to all individuals whose last 
MMR dose was more than 10 years ago [17], we specifi-
cally looked at the interval of 10 years since the second 
MMR dose.
A two-sided p-value of < 0.05 was considered statisti-
cally significant. Analyses were performed using Stata 
version 12.0 (StataCorp, College Station, Texas, US).
Results
Recruitment of cases and controls
Thirteen clusters with 2 to 19 cases were included. Two 
clusters could not be included due to organisational 
issues. Clusters were reported in five universities and 
two units of the same military barrack. Of the 5,652 
students invited, 427 responded to the web-based 
survey (response 8%). Of those, 72 students declared 
themselves as cases and 355 were classified as con-
trols. Sixty-one met the definition of a probable (n=47) 
or a confirmed case (n=14). In addition, we recruited 
104 individuals (20 confirmed cases, 6 probable cases 
and 78 controls) from the military (inclusion 96%). The 
initial database included 98 probable and confirmed 
cases (self-reported or diagnosed by a military doc-
tor) and 433 controls (Figure). This corresponds to 51% 
(98/194) of the initially reported cases. Individuals with 
no information on vaccination status were excluded. 
In addition, we excluded from the analysis eight self-
declared cases who did not meet the definition of a 
probable or confirmed case and 112 controls, either 
because they did not meet the definition of a control 
or because they had a history of mumps in the past. In 
total, 85 cases and 321 controls were included in the 
descriptive part of the study. For the logistic regression 
model we excluded individuals who were not vacci-
nated (n = 43), who did not have their vaccination dates 
documented (n = 66) and those who had received their 
last dose of MMR ≤ 3 weeks before the study (n = 10).
Description of cases and controls
Ninety-eight per cent of cases (83/85) presented with 
parotitis; two suffered from an inflammation of a sub-
maxillary gland and had a positive serology, one also 
had a positive PCR. The only complication reported was 
orchitis (Table 1). Among the five men who presented 
with orchitis (of 57 male cases), one had not been vac-
cinated; two were vaccinated with one MMR dose and 
two with two doses. Fifty of the 61 (82%) cases among 
university students reported that they had at least 
Table 2





(N = 321) p b
n % n %
Location of cluster unit a 
Military barracks 2 24 28 78 24
0.07 c
University in Pau 2 8 9.4 19 5.9
University in Lille 2 10 12 39 12
University A in Grenoble 4 26 31 74 23
University B in Grenoble 1 4 4.7 4 1.3
University and student party in Reims 2 13 15 107 33
Sex 
Men NA 57 67 176 55 0.04
MMR vaccination status 
Not vaccinated NA 15 18 28 8.7
0.06 d
1 dose NA 17 20 61 19
2 doses NA 50 59 199 62
Number of doses unknown NA 3 3.5 33 10
Time interval between doses 
Mean (IQR) NA 7.7 (3.3–10.0) 7.9 (5.1–10.0) 0.99
Age in years (mean and IQR) 
At the first MMR dose NA 2.9 (1–2) 3.9 (1–4) 0.22
At time of study NA 21.8 (21–23) 21.4 (20–22) 0.08
IQR: interquartile range; MMR: measles-mumps rubella vaccine; NA: not applicable.
a Cluster unit: ≥ 2 cases, of which ≥ 1 was laboratory confirmed, occurring within 3 months in 2013 in the same environment (university course, 
student party or military barracks)
b All p-values are derived by logistic regression
c Comparison refers to the 13 cluster units
d Comparison includes only individuals with zero, one or two doses
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one contact with at least one case before developing 
mumps.
Cases were more likely to be males than controls 
(p = 0.04) (Table 2). Cases and controls did not dif-
fer significantly in terms of age. There were more 
unvaccinated cases than controls, 18% (15/85) vs 9% 
(28/321), but the proportion of cases and controls vac-
cinated with two doses was similar, 59% (50/85) vs 
62% (199/321) (Table 2). Nobody had received more 
than two doses. Vaccine effectiveness among individu-
als who had received only one dose was 49% (adOR 
0.51; 95%CI 0.2–1.2) and 55% for two doses (adOR 
0.45; 95%CI 0.2–0.9), compared with unvaccinated 
individuals.
Association between the time since the last 
measles-mumps-rubella vaccine dose and the 
onset of mumps
The best-fitting fractional polynomial was a linear 
transformation of the time. This transformation was 
thus kept for further analysis.
Respondents with one or two measles-mumps-
rubella vaccine doses
When we restricted the analysis to the 60 cases and 
227 controls who had received at least one dose of 
MMR vaccination and for whom at least the date of the 
last dose was documented, the mean time from the 
last dose to symptom onset was 13 years (IQR 11–15 
years) for cases and from the last dose to the moment 
of study participation, 12 years (IQR 9–15 years) for 
controls. Adjusting for age, sex, cluster unit and num-
ber of MMR doses, the odds of mumps increased by 7% 
for every additional year in time since their last MMR 
dose (aOR: 1.07; 95%CI: 1.01–1.14).
Respondents with two measles-mumps-rubella 
vaccine doses
We further restricted the analysis to the 46 cases and 
172 controls who had two documented doses of MMR. 
Of those, 25 individuals (21 soldiers and 4 students) had 
received their second dose less than one year before 
the study began. The minimum time interval between 
two doses was 28 days. Time intervals between doses 
and the age at the first dose were not significantly dif-
ferent between cases and controls (Table 2). The mean 
time from the second dose to symptom onset was 12 
years (IQR 11–14 years) for cases and from the second 
dose to the moment of study participation 11 years (IQR 
9–14 years) for controls.
Adjusting for age, sex, and cluster unit, the odds of 
mumps increased by 10% for every year increase in 
time since the second dose (aOR 1.10; 95% CI: 1.02–
1.19). This odds increased by 162% (aOR 2.62; 95%CI 
1.9–5.8) for 10 years since the second dose, based on 
46 cases and 172 controls. 
Discussion
Mumps outbreaks occurred in France in 2013 in highly 
vaccinated young adults. We describe an associa-
tion between the time interval since the last dose of 
MMR vaccination and disease onset, with the odds of 
the disease increasing with increasing time since last 
vaccination. This suggests waning mumps-vaccine-
conferred immunity over time. The result was obtained 
using a logistic regression model. We also calculated 
incidence rate ratios using a Poisson regression model 
with a robust error variance (data not shown). We 
obtained similar results as with the logistic regression 
model, and thus we decided to keep the simpler model 
and to report ORs.
Our findings are consistent with observations of mumps 
outbreaks among highly vaccinated young adults in 
many countries in recent years, suggesting secondary 
vaccine failure: in Ireland (2004-05) [18], the US (2006 
and 2009-10) [3,10,16,19], England and Wales (2011) 
[14], Serbia (2012) [20] and the Netherlands (2013) [9]. 
Waning vaccine-conferred immunity in the absence of 
natural boosters in individuals who had received their 
last MMR dose many years before was suggested as 
one of the most important reasons contributing to the 
occurrence of outbreaks in highly vaccinated popula-
tions [9,14,16,21]. A combination of other suggested 
reasons included a lower-than-expected vaccine effec-
tiveness [21], insufficient two-dose vaccination cover-
age [13,18], short time interval between MMR doses 
[22], intense proximity in semi-closed populations 
[3,9,10,21], and mismatch of the vaccine virus strain 
with the circulating outbreak strains [21,23]. Several 
studies [15,16,24] indicated a high attack rate in indi-
viduals who were vaccinated more than 10 years pre-
viously. However, in most studies which evaluated the 
effect of time since MMR vaccination, cases’ age groups 
or birth cohorts were used as a proxy for the number 
of years since the last dose [22,25,26] assuming good 
adherence to national vaccination recommendations. 
Our study provides more robust evidence of waning 
immunity, as our estimates were based on actual vac-
cination dates. Since the MMR vaccination schedule 
in France has changed several times during the child-
hoods of the population concerned, including catch-
up vaccinations at different time points, we could not 
assume uniform vaccination history. Those differences 
of the second dose’s timing, even within the same birth 
cohort, allowed us to measure the association between 
timing of the second dose and disease onset. We did 
not find any significant difference between cases and 
controls in the time intervals between the two doses. In 
a model without the variable ‘time since last dose’, the 
variable ‘age at first dose’ was associated with mumps 
occurrence (data not shown). However, when including 
both variables in a model, none of the aORs was sta-
tistically significant, even though both point estimates 
were only slightly modified. We concluded that the 
reason for not getting significant results when we are 
including both variables in the same model is mainly 
a lack of statistical power and that both variables are 
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independently associated with the outcome. A recent 
study of measles showed an association between age 
at first MMR dose and measles occurrence [27], which 
may possibly apply to mumps too and deserves fur-
ther investigation. In similar future studies, which may 
include a larger number of individuals, adjustment for 
age at the first dose should be undertaken.
A further limitation of our study is the fact that vac-
cination history was self-reported by the students. To 
reduce inaccuracy and to obtain reliable information 
on vaccination history, only students who documented 
vaccination dates according to their vaccination or 
health booklets were included in the analytical part of 
the study. The low response to the online survey at the 
universities may be due to the fact that we surveyed 
the students 1 to 4 months after the start of the dif-
ferent outbreaks and after initial investigations had 
already been carried out. It is conceivable that controls 
who had recently been vaccinated had a greater aware-
ness of the topic and responded more willingly than 
individuals whose vaccination was longer ago. To limit 
this possible participation bias and increase response, 
we contacted students repeatedly by email and tele-
phone and visited some of the universities. Symptoms 
were also self-reported by the students which might 
have led to over-reporting of disease. To increase spec-
ificity, we only included probable and confirmed cases 
and requested at least one laboratory-confirmed case 
per cluster. Due to the nature of the organisation of 
the army, there was a higher percentage of laboratory-
confirmed cases among soldiers than among students. 
For the soldiers, the investigators were able to con-
sult laboratory results in the medical files. Students 
self-reported their biological confirmation. This is a 
difference in reliability between data of soldiers and 
students, but outbreak investigation teams who had 
undertaken site visits to the universities in order to 
confirm the outbreak before the study had seen the 
laboratory results of the initial cases.
In older age groups, complications of mumps are more 
frequent and more severe than in children [2,14]. This 
is especially true for unvaccinated individuals [9,14]. 
Before the introduction of MMR vaccination, mumps 
was the primary cause of viral meningitis and a leading 
cause of hearing loss in children [28,29]. In our study, 
we observed few complications (orchitis in 9% of 
male cases). The small size of our study did not allow 
detection of differences in complication rates by vac-
cination status. However, the low overall incidence of 
complications is in line with what was described after 
introduction of MMR vaccination by previous stud-
ies [3,10]. In an outbreak in the Netherlands in 2013 
among a predominantly vaccinated population (78% 
one-dose vaccination coverage), orchitis and all-cause 
hospitalisations were significantly lower in individu-
als vaccinated with one dose and lower still in those 
vaccinated twice [9]. Similar findings were described 
in England and Wales (in 2004–2005) [14]. This sug-
gests that although mumps vaccination may not confer 
long-term protection against the disease, a previously 
vaccinated individual is able to mount a rapid immune 
response which is sufficient to reduce complications 
significantly [14].
Age at mumps infection in France, as well as in other 
countries, has shifted from childhood to adolescence 
and young adulthood following the introduction of 
MMR vaccination in the routine childhood immunisa-
tion schedules [2,9,10,14,18]. The majority of cases in 
our study population were vaccinated in childhood and 
had low residual protection in young adulthood, with 
little difference between those who had received one 
or two doses. The relatively high number of individuals 
who got their second dose during the year before the 
study is related to the fact of most of them were young 
soldiers who had their vaccination status reviewed 
and updated when entering the army. In France, peo-
ple born before the 1980s were not vaccinated against 
mumps. However, due to the wide circulation of the 
virus in the community before the introduction of vac-
cination, they are likely to have had natural mumps 
infection and have thus acquired long-lasting pro-
tection. In 2013, at the time of the occurrence of the 
described clusters, those individuals born before the 
1980s were ≥ 33 years old and no cases were reported 
among them. Only young adults (the mean age of cases 
was 22 years) in environments prone to intense social 
mixing were included in the study. Extrapolation of our 
results to other populations needs to be undertaken 
with great caution.
One of the possible responses to confer a better level 
of immunity in young adults could be to postpone the 
administration of the second MMR dose until later in 
adolescence [21]. However, we observed a very low 
one-dose VE (48%) in our study population and VE in 
the general population is reported to be between 62% 
and 85% [15]. This low VE and the fact that the vaccine 
is commonly administered in combination with mea-
sles and rubella vaccines do not favour such approach. 
Likewise, we cannot hope for the availability of a vac-
cine with a higher effectiveness in the near future.
Waning mumps-vaccination-conferred immunity and 
the occurrence of outbreaks in highly vaccinated pop-
ulations suggest the need for a third MMR dose. The 
administration of a targeted third dose in schools has 
been experimented with in the US during two outbreaks 
in 2009 and 2010 [3,19]: In both instances attack rates 
declined markedly during the weeks following the inter-
vention. However, the decline in the number of new 
cases may have been partly attributable to the natu-
ral dynamics of the epidemics. Nevertheless, those 
and other experiences suggest that a third-dose inter-
vention may be an appropriate measure to limit the 
propagation of outbreaks and a good control measure 
in highly vaccinated, relatively closed populations. In 
addition, low rates of vaccination side effects of a third 
dose were reported in both studies [3,19]. This seems 
plausible as the vaccine virus will rapidly be inactivated 
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by pre-existing antibodies when administering a live 
attenuated vaccine to a person with remaining immu-
nity from a previous vaccination.
The Netherlands has considered the introduction of a 
regular third dose in the national vaccination schedule 
but abandoned the idea because mumps-associated 
morbidity was relatively low and vaccine uptake of a 
third dose was unlikely to be satisfactory [9].
Since 1991, all new recruits to the US army receive a 
MMR vaccination regardless of their previous vacci-
nation status and thus, in many cases, a third dose. 
Before 1991, outbreaks regularly occurred among US 
soldiers [30]. During the 2006 outbreak in the US, 
which involved mainly adults aged 18 to 24 years, not a 
single case in this age group was reported in American 
troops [31]. However, the American recommendation is 
limited to army personnel.
Following the upsurge of mumps in 2013, and taking 
into consideration the high proportion of cases vac-
cinated with two doses, the French HCSP has recom-
mended a third dose in outbreak settings involving 
semi-closed populations (schools, universities, board-
ing schools, barracks, sport clubs, etc.) for individuals 
vaccinated > 10 years earlier [17]. Our preliminary study 
results substantiated this decision. This recommenda-
tion goes alongside catch-up vaccination of non- or 
partially vaccinated individuals.
The third-dose strategy will not prevent disease in 
already-infected contact persons, but rather limit the 
size of the outbreak and avoid further spread. In addi-
tion to avoiding further cases, the third dose might 
help to limit complications. Although there is no good 
evidence for the usefulness of the vaccination in indi-
viduals who are already incubating the virus, a shorten-
ing of the period of virus shedding is conceivable [32].
In addition to the above-mentioned limitations, con-
trols’ probability of exposure to the virus may have 
been overestimated if contact with cases was not as 
close as assumed. Most cluster units had a high num-
ber of cases and in most universities we found clus-
ters in different courses or years. We thus considered 
viral circulation as sufficiently dense to make the 
assumption that cases and controls had equal prob-
ability of being exposed. The number of asymptomati-
cally infected individuals was probably not negligible. 
In a serological study from the Netherlands, inves-
tigating mumps antibody titres before and after an 
outbreak, the authors showed an attack rate almost 
two-fold higher in asymptomatic individuals compared 
with symptomatic persons [33]. However, the role of 
asymptomatically infected individuals for transmission 
remains unclear.
Strain identification of the virus would have been 
additional interesting information. However, this was 
beyond the scope of this study.
Our study suggests that mumps vaccine effectiveness 
wanes with time. Our findings substantiate the intro-
duction of a targeted third dose in outbreak settings 
for individuals with > 10 years after the last dose. Future 
observations in France and possibly other countries 
which might introduce the same recommendation or a 
recommendation with different inclusion criteria for a 
third dose, will determine whether the approach of a 
third MMR dose is an effective public health interven-
tion for limiting mumps outbreaks.
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